platinum has been researched along with Peritoneal Neoplasms in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.56) | 18.7374 |
| 1990's | 5 (12.82) | 18.2507 |
| 2000's | 2 (5.13) | 29.6817 |
| 2010's | 20 (51.28) | 24.3611 |
| 2020's | 11 (28.21) | 2.80 |
| Authors | Studies |
|---|---|
| Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Buza, N; Clark, M; Harold, J; Huang, GS; Hui, P; Mauricio, D; Menderes, G; Rao, GG; Ratner, E; Reader, JC; Roque, DM; Santin, AD; Schwartz, PE; Siegel, ER; Silasi, DA; Tymon-Rosario, JR; Zeybek, B | 1 |
| Boerma, D; Constantinides, A; de Hingh, IHJT; Elias, SG; Huitema, ADR; Koster, J; Kranenburg, O; Laoukili, J; Nienhuijs, SW; Raats, DAE; Rinkes, IHMB; van Grevenstein, HMU; van Schelven, SJ; van Wettum, J; Volckmann, R; Wassenaar, ECE; Wiezer, RJ | 1 |
| Hirata, M; Ishikawa, M; Noguchi, E; Odaka, Y; Saito, A; Shimoi, T; Sudo, K; Tanioka, M; Watanabe, T; Yonemori, K | 1 |
| Ma, J; Zhang, S | 1 |
| Abe, M; Aida, T; Baba, T; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takatori, E; Tatsuki, S; Tomabechi, H | 1 |
| Cengel, K; Ciunci, C; Karakousis, G; Katz, S; Langer, CJ; Marmarelis, ME; McNulty, S; Miura, J; Roshkovan, L; Walker, S; Wang, X | 1 |
| Baba, T; Furukawa, S; Kagabu, M; Kaiho-Sakuma, M; Matsumura, Y; Nagasawa, T; Nagase, S; Ohta, T; Seino, M; Shigeta, S; Shigeto, T; Shimada, M; Shimizu, D; Shoji, T; Soeda, S; Takahashi, F; Takatori, E; Terada, Y; Tokunaga, H; Watanabe, T; Yokoyama, Y | 1 |
| Aghajanian, C; Chi, DS; Chui, MH; Girshman, J; Gordhandas, S; Grisham, RN; Iasonos, A; Kahn, RM; Laibangyang, A; Long Roche, K; Manning-Geist, BL; Nemirovsky, D; Zivanovic, O | 1 |
| Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T | 1 |
| Cheng, C; Cheng, P; Hu, S; Li, X; Liu, G; Liu, Q; Lu, Y; Su, B; Wang, L; Wang, N; Xu, J; Zhu, L | 1 |
| Adorno-Cruz, V; Berry, E; Cowan, M; Kocherginsky, M; Lurain, JR; Matei, D; Nelson, V; Neubauer, NL; O'Shea, KL; Pineda, MJ; Shahabi, S; Swetzig, WM; Taiym, D | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L | 1 |
| Fujiwara, H; Hamano, T; Itamochi, H; Kamiura, S; Kato, K; Kigawa, J; Komiyama, S; Shoji, T; Sugiyama, T; Tanabe, H | 1 |
| Amira, G; Fayek, IS; Mansour, O; Morsi, A; Nader, H | 1 |
| Aasheim, LB; Abrahamsen, TW; Davidson, B; Dybdahl, B; Flatmark, K; Fromm, B; Hovig, E; Julsrud, L; Kristensen, AT; Larsen, SG; Lund-Andersen, C; Nakken, S; Nygård, S | 1 |
| Alconchel, F; Barceló, F; Cascales-Campos, PA; Gil, E; Gil, J; Gómez-Ruiz, ÁJ; González-Gil, A; Martínez, J; Navarro-Barrios, Á; Nieto, A | 1 |
| Li, Y; Li, Z; Lu, L; Xie, X; Xiong, T | 1 |
| Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y | 1 |
| Butow, P; Donovan, H; Friedlander, ML; Gillies, K; King, MT; Martyn, J; O'Connell, R; Oza, A; Sjoquist, K; Stockler, M; Voysey, M | 1 |
| Abiko, K; Baba, T; Chikuma, S; Hamanishi, J; Honjo, T; Hosoe, Y; Ikeda, T; Kanai, M; Kawaguchi, A; Konishi, I; Mandai, M; Matsumoto, S; Matsumura, N; Minami, M; Mori, Y; Morita, S; Murayama, T; Shimizu, A; Ueda, A; Yamaguchi, K; Yokode, M | 1 |
| Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Peng, CW | 1 |
| Allen, AR; Bell-McGuinn, KM; Brenton, JD; Coleman, RL; Cragun, JM; Floquet, A; Giordano, H; Goble, S; Harding, TC; Harrell, MI; Isaacson, J; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; Mann, E; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Raponi, M; Ray-Coquard, I; Rolfe, L; Scott, CL; Sun, J; Swisher, EM; Tinker, AV; Yelensky, R | 1 |
| Barbieri, P; Brienza, S; Carminati, P; Colombo, N; du Bois, A; Frigerio, L; Guastalla, JP; Katsaròs, D; Lhommé, C; Lissoni, AA; Parma, G; Pecorelli, S; Poveda, A; Ray-Coquard, I; Tisi, G; Tredan, O; Vermorken, JB | 1 |
| Fernandez, G; Garnier, R; Hasni-Pichard, H; Konate, A; Mezzaroba, D; Pocard, M; Poupon, J; Villa, A | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Arnold, AG; Grisham, RN; Hyman, DM; Iasonos, A; Kauff, ND; Spriggs, D; Zhou, Q | 1 |
| Enomoto, T; Kim, A; Naka, T; Ueda, Y | 1 |
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
| Dodič-Fikfak, M; Dolžan, V; Erčulj, N; Franko, A; Hmeljak, J; Kovač, V | 1 |
| Verhulst, J | 1 |
| Goff, BA; Greer, BE; Jacobs, A; Storer, B; Thompson, T | 1 |
| Akamo, Y; Manabe, T; Mizuno, I; Mohri, N; Shibata, T; Takeyama, H; Terada, J; Ueda, T; Yamamoto, T; Yotsuyanagi, T | 1 |
| Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG | 1 |
| Ikeguchi, M; Kaibara, N; Maeta, M | 1 |
| den Engelse, L; Los, G; McVie, JG; Pinedo, HM; Smals, OA; van der Vlist, M; van Vugt, MJ | 1 |
| Gonzalez-Gonzalez, D; Havemen, J; Los, G; McVie, JG; Mutsaers, PH; Smals, O; Sminia, P; ten Bokkel Huinink, D; Wondergem, J | 1 |
| Baldew, GS; Lenglet, WJ; Los, G; McVie, JG; Mutsaers, PH | 1 |
| Issell, BF; Krikorian, JG; Lee, FH; Lopez, JA; Reich, SD; Smyth, RD | 1 |
1 review(s) available for platinum and Peritoneal Neoplasms
| Article | Year |
|---|---|
Therapeutic strategies in epithelial ovarian cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Taxoids | 2012 |
9 trial(s) available for platinum and Peritoneal Neoplasms
| Article | Year |
|---|---|
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Epothilones; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum | 2022 |
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors | 2021 |
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Platinum; Quinolines | 2021 |
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizuma
Topics: Antineoplastic Agents; Bevacizumab; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Progression-Free Survival | 2018 |
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Programmed Cell Death 1 Receptor; Salvage Therapy; Survival Rate | 2015 |
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Topics: Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Indoles; International Agencies; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate | 2017 |
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Recurrence; Taxoids | 2010 |
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Washington | 2003 |
29 other study(ies) available for platinum and Peritoneal Neoplasms
| Article | Year |
|---|---|
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity.
Topics: Colorectal Neoplasms; Humans; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Platinum | 2022 |
Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
Topics: Adenosine Diphosphate; Aged; BRCA1 Protein; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
Topics: Female; Humans; Ki-67 Antigen; Mesothelioma, Malignant; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies | 2022 |
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies | 2022 |
A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Humans; Mesothelioma, Malignant; Middle Aged; Peritoneal Neoplasms; Peritoneum; Platinum; Retrospective Studies | 2022 |
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Progression-Free Survival; Retrospective Studies | 2022 |
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cystadenocarcinoma, Serous; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies | 2023 |
Implantable platinum nanotree microelectrode with a battery-free electrochemical patch for peritoneal carcinomatosis monitoring.
Topics: Animals; Biosensing Techniques; Electric Power Supplies; Humans; Microelectrodes; Peritoneal Neoplasms; Platinum; Rats | 2021 |
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment | 2018 |
Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate; United States; Young Adult | 2019 |
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genetic Variation; Genomics; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Palliative Care; Pemetrexed; Peritoneal Neoplasms; Platinum; Treatment Outcome; Young Adult | 2019 |
Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Nomograms; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Prospective Studies; Severity of Illness Index; Survival Rate; Taxoids | 2019 |
In vivo monitoring the process of tumor growth, metastasis and bacterial infection expressing GFP via real-time optical imaging.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Computer Systems; Escherichia coli Infections; Fluorescence; Green Fluorescent Proteins; Humans; Kanamycin; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasms; Optical Imaging; Peritoneal Neoplasms; Platinum; Rats; Subcutaneous Tissue | 2013 |
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Palliative Care; Peritoneal Neoplasms; Platinum; Prognosis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires | 2014 |
Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Databases, Factual; Disease-Free Survival; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Propensity Score | 2016 |
Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure.
Topics: Air Pollutants, Occupational; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Environmental Monitoring; Gloves, Surgical; Humans; Hyperthermia, Induced; Infusions, Parenteral; Inhalation Exposure; Medical Staff, Hospital; Occupational Exposure; Operating Rooms; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Platinum | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan | 2011 |
DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Cycle Proteins; Deoxycytidine; DNA; DNA Repair; DNA-Binding Proteins; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Nuclear Proteins; Peritoneal Neoplasms; Platinum; Pleural Effusion, Malignant; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Rad51 Recombinase; Survival Rate; X-ray Repair Cross Complementing Protein 1 | 2012 |
Effects of bevacizumab and hyperthermia in a rodent model of hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; HT29 Cells; Humans; Hyperthermia, Induced; Male; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Platinum; Rats; Rats, Nude; Tumor Burden | 2013 |
[Intraperitoneal administration of carboplatin loaded alpha-tricalcium phosphate (alpha-TCP) particles in rats bearing abdominal carcinomatosis].
Topics: Animals; Antineoplastic Agents; Ascites; Biodegradation, Environmental; Calcium Phosphates; Carboplatin; Disease Models, Animal; Drug Carriers; Infusions, Parenteral; Male; Peritoneal Neoplasms; Platinum; Rats | 1996 |
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome | 1998 |
Cisplatin combined with prostaglandin E1 chemotherapy in rat peritoneal carcinomatosis.
Topics: Alprostadil; Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Cytoprotection; Drug Therapy, Combination; Kidney; Male; Peritoneal Neoplasms; Platinum; Rats | 2000 |
A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Topics: Adenocarcinoma; Animals; Body Temperature; Carboplatin; Colonic Neoplasms; Combined Modality Therapy; Hyperthermia, Induced; Injections, Intraperitoneal; Injections, Intravenous; Male; Peritoneal Neoplasms; Platinum; Rats; Tissue Distribution | 1992 |
Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats.
Topics: Animals; Cisplatin; Hyperthermia, Induced; Male; Neoplastic Stem Cells; Peritoneal Neoplasms; Platinum; Rats; Rats, Inbred Strains; Temperature; Tissue Distribution; Tumor Cells, Cultured | 1991 |
Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.
Topics: Animals; Autoradiography; Cisplatin; Injections, Intraperitoneal; Injections, Intravenous; Kidney; Male; Peritoneal Neoplasms; Platinum; Rats; Rats, Inbred Strains; Spectrometry, X-Ray Emission; Tissue Distribution | 1990 |
Clinical pharmacology of intraperitoneal cisplatin.
Topics: Aged; Ascitic Fluid; Cisplatin; Drug Evaluation; Female; Humans; Injections, Intraperitoneal; Kinetics; Mesothelioma; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Spectrophotometry, Atomic | 1985 |